Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...

Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. These figures are ...

Idaho – which finished 11-21, with a 5-13 mark in the Big Sky – won half of its preseason games before coming up with some ...

Reports Q3 revenue $11.8M, consensus $7.83M. “I’m encouraged by our continued operational effectiveness, with phase 3 trials accelerating for ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...

UBS Group assumed coverage on shares of Merus (NASDAQ:MRUS – Free Report) in a research note released on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $72.00 ...

Team Rebounds: 6. Team Turnovers: None. Blocked Shots: 4 (Crujeiras, Martin, Potter, Whalen). Turnovers: 19 (Whalen 4, Aubry-Thomas 3, Hagan 3, Mugosa 2, Potter 2, Williams 2, Hansen, Martin, Zapater) ...